US FDA In ‘First Stages’ Of Reconsidering Black Box For Antipsychotics

 
• By Ramsey Baghdadi

Patient advocates and sponsors want the US to reconsider a 20-year-old class warning against the use of antipsychotics in patients with dementia. The agency is weighing the issue, but also defending the current labels of newer agents.

Sponsors want the boxed warning for antipsychotic drugs applied on a case-by-case basis rather than class-wide. (Shutterstock)

More from Drug Safety

More from Product Reviews